Evonile Pharma Limited (BOM:500672)

Market Cap	46.93B +120.7%
Revenue (ttm)	3.71B +5.4%
Net Income	977.70M -4.9%
EPS	39.60 -4.9%
Shares Out	24.69M
PE Ratio	48.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,814
Open	1,919.85
Previous Close	1,937.30
Day's Range	1,850.00 - 1,941.00
52-Week Range	750.00 - 2,588.00
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Evonile Pharma

Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai,...

• Industry: Pharmaceutical Preparations
• Founded: 1947
• Employees: 57
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500672

Financial Performance

In fiscal year 2026, Evonile Pharma's revenue was 3.54 billion, a decrease of -0.54% compared to the previous year's 3.56 billion. Earnings were 931.80 million, a decrease of -7.65%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 17, 2026

Data Sources Report a data error